Vigier S, Gagnon H, Bourgade K, Klarskov K, Fulop T and Vermette P. Composition and organization of the pancreatic extracellular matrix by combined methods of immunohistochemistry, proteomics and scanning electron microscopy. Current research in translational medicine. 2017.

Lien ResearchGate


Ly K, Essalmani R, Desjardins R, Seidah N, Day R. An unbiaised mass spectrometry approach identifies Glypican-3 as an interactor of Proprotein convertase Subtilisin/Kexin type 9 (PCSK9) and LDL Receptor in hepatocellular carcinoma cells. JBC. 2017.

Lien direct


Savard M, Côté J, Tremblay L, Neugebauer W, Regoli D, Gariépy S, Hébert N, Gobeil F.

Safety and pharmacokinetics of a kinin B1 receptor peptide agonist produced with different counter-ions.

Biol Chem. 2015 Dec 12.



Duhamel M, Rodet F, Delhem N, Vanden Abeele F, Kobeissy F, Nataf S, Pays L, Desjardins R, Gagnon H, Wisztorski M, Fournier I, Day R, Salzet M.

Molecular consequences of proprotein convertase 1/3 inhibition in macrophages for application to cancer immunotherapy: a proteomic study.

Mol Cell Proteomics. 2015



Semaan W, Desbiens L, Houde M, Labonté J, Gagnon H, Yamamoto D, Takai S, Laidlaw T, Bkaily G, Schwertani A, Pejler G, Levesque C, Desjardins R, Day R, D'Orléans-Juste P.

Chymase inhibitor-sensitive synthesis of endothelin-1 (1-31) by recombinant mouse mast cell protease 4 and human chymase.

Biochem Pharmacol. 2015



Parent AJ, Beaudet N, Daigle K, Sabbagh R, Sansoucy Y, Marchand S, Sarret P, Goffaux P.

Relationship between blood- and cerebrospinal fluid-bound neurotransmitter concentrations and conditioned pain modulation in pain-free and  chronic pain subjects.

J Pain. 2015



Levesque C, Couture F, Kwiatkowska A, Desjardins R, Guérin B, Neugebauer WA, Day R.

PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation.

Oncotarget. 2015



Kwiatkowska A, Couture F, Levesque C, Ly K, Desjardins R, Beauchemin S, Prahl A, Lammek B, Neugebauer W, Dory YL, Day R.

Design, synthesis, and structure-activity relationship studies of a potent PACE4 inhibitor.

J Med Chem. 2014



Gagnon H, Beauchemin S, Kwiatkowska A, Couture F, D'Anjou F, Levesque C, Dufour F, Desbiens AR, Vaillancourt R, Bernard S, Desjardins R, Malouin F, Dory YL, Day R.

Optimization of furin inhibitors to protect against the activation of influenza hemagglutinin H5 and Shiga toxin.

J Med Chem. 2014



Kay P, Wagner JR, Gagnon H, Day R, Klarskov K.

Modification of peptide and protein cysteine thiol groups by conjugation with a degradation product of ascorbate.

Chem Res Toxicol. 2013



Longuespée R, Gagnon H, Boyon C, Strupat K, Dauly C, Kerdraon O, Ighodaro A, Desmons A, Dupuis J, Wisztorski M, Vinatier D, Fournier I, Day R, Salzet M.

Proteomic analyses of serous and endometrioid epithelial ovarian cancers - cases studies - molecular insights of a possible histological etiology of serous ovarian cancer.

Proteomics Clin Appl. 2013



Levesque C, Fugère M, Kwiatkowska A, Couture F, Desjardins R, Routhier S, Moussette P, Prahl A, Lammek B, Appel JR, Houghten RA, D'Anjou F, Dory YL, Neugebauer W, Day R.

The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells.

J Med Chem. 2012